ABT:NYE-Abbott Laboratories (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 104.23

Change

-0.59 (-0.56)%

Market Cap

USD 56.45B

Volume

5.83M

Analyst Target

USD 115.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SYK Stryker Corporation

N/A

USD 131.96B
BSX Boston Scientific Corp

N/A

USD 113.42B
MDT Medtronic PLC

N/A

USD 108.64B
EW Edwards Lifesciences Corp

N/A

USD 52.43B
PHG Koninklijke Philips NV ADR

N/A

USD 24.63B
STE STERIS plc

N/A

USD 22.30B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 22.20B
SNN Smith & Nephew SNATS Inc

N/A

USD 11.14B
GMED Globus Medical

N/A

USD 8.83B
BIO Bio-Rad Laboratories Inc

N/A

USD 8.06B

ETFs Containing ABT

UMDV:SW iShares US Medical Device.. 16.55 % 0.00 %

N/A

USD 0.23B
IHI iShares U.S. Medical Devi.. 16.53 % 0.43 %

N/A

USD 5.24B
EDOC:AU BetaShares Digital Health.. 7.92 % 0.00 %

N/A

N/A
HART IQ Healthy Hearts ETF 4.26 % 0.00 %

N/A

USD 9.35M
XGSD:SW Xtrackers Stoxx Global Se.. 4.14 % 0.00 %

N/A

USD 0.63B
XGSD:XETRA Xtrackers Stoxx Global Se.. 4.14 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.07 % 0.00 %

N/A

USD 3.55M
XGES:LSE Xtrackers MSCI Genomic He.. 4.07 % 0.00 %

N/A

USD 3.55M
SXLV:SW SPDR S&P U.S. Health Care.. 3.54 % 0.00 %

N/A

N/A
PWV Invesco Dynamic Large Cap.. 3.46 % 0.55 %

N/A

USD 0.91B
WELG:XETRA Amundi S&P Global Health .. 3.44 % 0.00 %

N/A

USD 0.24B
WELS:XETRA Amundi S&P Global Health .. 3.44 % 0.00 %

N/A

USD 0.24B
QLTY GMO U.S. Quality ETF 3.42 % 0.00 %

N/A

USD 0.44B
IUHC:LSE iShares S&P 500 USD Healt.. 3.35 % 0.00 %

N/A

USD 2.29B
ZPDH:F SPDR S&P U.S. Health Care.. 3.34 % 0.00 %

N/A

USD 0.40B
GXLV:LSE SPDR® S&P® U.S. Health .. 3.34 % 0.00 %

N/A

USD 0.38B
IUHC:SW iShares S&P 500 Health Ca.. 3.33 % 0.00 %

N/A

USD 2.29B
QDVG:F iShares S&P 500 Health Ca.. 3.32 % 0.00 %

N/A

USD 2.09B
XSHC:LSE Xtrackers MSCI USA Health.. 3.27 % 0.00 %

N/A

USD 0.79B
XUHC:LSE Xtrackers MSCI USA Health.. 3.27 % 0.00 %

N/A

USD 0.79B
XUHC:F Xtrackers (IE) Public Lim.. 3.27 % 0.00 %

N/A

USD 0.85B
XUHC:SW Xtrackers MSCI USA Health.. 3.27 % 0.00 %

N/A

USD 0.79B
DRUG:AU BetaShares Global Healthc.. 3.04 % 0.00 %

N/A

USD 0.17B
AIVL WisdomTree Trust - Wisdom.. 2.96 % 0.00 %

N/A

USD 0.38B
HEAL:CA 2.82 % 0.00 %

N/A

N/A
CGDV Capital Group Dividend Va.. 2.54 % 0.00 %

N/A

USD 8.30B
CURE Direxion Daily Healthcare.. 2.48 % 1.06 %

N/A

USD 0.20B
CGUS Capital Group Core Equity.. 2.22 % 0.00 %

N/A

USD 2.83B
HYLG Global X Funds - Global X.. 1.56 % 0.00 %

N/A

USD 2.85M
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

N/A

USD 3.03B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

USD 3.35B
JHMH 0.00 % 0.46 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD 0.27B
QDYN 0.00 % 0.37 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 4.67B
RWDC 0.00 % 0.00 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

USD 0.85M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD 0.85M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD 0.09B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

USD 17.71B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

CAD 0.60B
XLV Health Care Select Sector.. 0.00 % 0.13 %

N/A

USD 39.31B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

CAD 0.01B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

USD 1.69B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.39B
XGDD:LSE Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

USD 0.61B
XGSD:LSE Xtrackers Stoxx Global Se.. 0.00 % 0.00 %

N/A

USD 0.61B
DXSB:F Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

USD 0.62B
DXSB:XETRA Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

USD 0.68B
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

USD 2.05B
XDWH:XETRA Xtrackers MSCI World Heal.. 0.00 % 0.00 %

N/A

USD 2.60B
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IXJ:AU iShares Global Healthcare.. 0.00 % 0.00 %

N/A

USD 1.35B
ANEW ProShares MSCI Transforma.. 0.00 % 0.00 %

N/A

USD 8.48M
FUD-A:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.31% 50% F 21% F
Dividend Return 1.00% 86% B+ 43% F
Total Return -4.31% 56% F 21% F
Trailing 12 Months  
Capital Gain 2.05% 57% F 33% F
Dividend Return 2.08% 71% C- 30% F
Total Return 4.12% 57% F 28% F
Trailing 5 Years  
Capital Gain 35.40% 53% F 62% D
Dividend Return 11.56% 88% B+ 44% F
Total Return 46.96% 58% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.27% 56% F 63% D
Dividend Return 8.97% 59% D- 61% D-
Total Return 1.69% 78% C+ 40% F
Risk Return Profile  
Volatility (Standard Deviation) 19.04% 88% B+ 58% F
Risk Adjusted Return 47.10% 85% B 69% C-
Market Capitalization 56.45B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.70 86% 21%
Price/Book Ratio 4.90 35% 18%
Price / Cash Flow Ratio 25.11 30% 12%
Price/Free Cash Flow Ratio 18.75 34% 16%
Management Effectiveness  
Return on Equity 14.76% 94% 72%
Return on Invested Capital 10.37% 88% 66%
Return on Assets 6.09% 91% 79%
Debt to Equity Ratio 35.23% 70% 69%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector